Published in J Natl Cancer Inst on March 02, 1988
Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol (1990) 2.07
P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer (1989) 1.39
An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. Am J Pathol (1990) 1.35
Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci U S A (1989) 1.34
Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci U S A (1988) 1.32
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics (2011) 1.29
Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer (1995) 1.16
P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer (1990) 1.15
Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer (2003) 1.12
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci U S A (1996) 1.11
Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am J Pathol (1991) 0.98
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol (2008) 0.94
Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl Acad Sci U S A (1991) 0.93
Reversal of multidrug resistance by surfactants. Br J Cancer (1992) 0.91
DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer (1989) 0.89
Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines. Br J Cancer (1991) 0.88
Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer (1991) 0.87
Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Br J Cancer (1996) 0.86
Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line. Br J Pharmacol (2004) 0.86
Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J Gastroenterol (2006) 0.85
Increased expression and DNA-binding activity of transcription factor Sp1 in doxorubicin-resistant HL-60 leukemia cells. Mol Cell Biol (1990) 0.85
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy? Br J Cancer (1997) 0.85
Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br J Cancer (1993) 0.83
In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs (2003) 0.82
Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol (2008) 0.82
Chemotherapeutic drug resistance in the management of head and neck cancer. Eur Arch Otorhinolaryngol (1993) 0.81
Amplicon structure in multidrug-resistant murine cells: a nonrearranged region of genomic DNA corresponding to large circular DNA. Mol Cell Biol (1992) 0.81
A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines. Br J Cancer (1992) 0.79
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells. Br J Cancer (1993) 0.78
A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer (1992) 0.78
Requirement for metabolic activation of acetylaminofluorene to induce multidrug gene expression. Environ Health Perspect (1994) 0.77
Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol (1995) 0.77
Expression of anionic glutathione S transferase (GST pi) gene in carcinomas of the uterine cervix and in normal cervices. Br J Cancer (1991) 0.75
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem (1986) 2.88
The pharmacology and clinical use of methotrexate. N Engl J Med (1983) 2.29
Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci U S A (1988) 1.86
Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res (1989) 1.86
Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res (1994) 1.73
Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. Clin Cancer Res (1995) 1.72
Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci U S A (1986) 1.71
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem (2000) 1.57
Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res (1997) 1.50
Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res (1987) 1.49
Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med (1983) 1.44
Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res (1995) 1.43
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2000) 1.43
An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. Am J Pathol (1990) 1.35
Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ (1996) 1.32
Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GST pi gene and its effect on sensitivity to toxins. Mol Pharmacol (1989) 1.29
Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res (1995) 1.26
A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem (1994) 1.23
Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci U S A (1987) 1.21
Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res (1995) 1.20
Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res (1995) 1.18
Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res (1996) 1.17
Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem (1982) 1.17
Isolation, characterization, and expression in Escherichia coli of two murine Mu class glutathione S-transferase cDNAs homologous to the rat subunits 3 (Yb1) and 4 (Yb2). J Biol Chem (1989) 1.15
Structure of the human genomic glutathione S-transferase-pi gene. Gene (1989) 1.13
Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene (2007) 1.13
Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun (1991) 1.10
Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response. Oncogene (2010) 1.09
A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol (1988) 1.08
Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry (1987) 1.06
BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene (1999) 1.05
A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem (1993) 1.05
Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Differ (1995) 1.03
Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis (1994) 0.99
Examination of human tumors for rhoA mutations. Oncogene (1994) 0.98
Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res (1992) 0.98
Isolation and characterization of genomic sequences involved in the regulation of the human reduced folate carrier gene (RFC1). Gene (1999) 0.97
Immunohistochemical expression of pi-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate. Cancer (1997) 0.97
Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy. Cancer Res (1986) 0.97
A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J Biol Chem (1984) 0.96
Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. Mol Pharmacol (1990) 0.96
Glutathione S-transferases and drug resistance. Cancer Cells (1990) 0.96
Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood (1995) 0.94
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res (1995) 0.93
Regulation of dihydrofolate reductase in human breast cancer cells and in mutant hamster cells transfected with a human dihydrofolate reductase minigene. Mol Pharmacol (1986) 0.93
Structure and function of the 5'-flanking sequence of the human cytosolic selenium-dependent glutathione peroxidase gene (hgpx1). J Biol Chem (1992) 0.93
Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Blood (1997) 0.93
Detection of circulating tumor cells and micrometastases in stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry. Diagn Cytopathol (2000) 0.93
Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res (1995) 0.92
5' Nucleotide sequences influence serum-modulated expression of a human dihydrofolate reductase minigene. Mol Cell Biol (1986) 0.92
Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol (2000) 0.92
Reversible transcriptional activation of mdr1 by sodium butyrate treatment of human colon cancer cells. J Biol Chem (1994) 0.92
Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. Cancer Res (1991) 0.92
Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. Cancer Commun (1989) 0.91
Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J Biol Chem (1988) 0.90
Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: effect on cellular sensitivity to cytotoxic agents. Mol Pharmacol (1992) 0.90
Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. Br J Cancer (1995) 0.90
Posttranscriptional control of glutathione S-transferase pi gene expression in human breast cancer cells. J Biol Chem (1992) 0.89
Monoclonal antibodies to glutathione S-transferase pi-immunohistochemical analysis of human tissues and cancers. Int J Cancer (1991) 0.89
Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases. Cancer Invest (1995) 0.89
Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells. Oncogene (1995) 0.89
Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol (2001) 0.89
Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol (1987) 0.89
Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst (1994) 0.88
Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol (1990) 0.88
Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line. Cancer Res (1985) 0.88
Intestinal folate transport: identification of a cDNA involved in folate transport and the functional expression and distribution of its mRNA. Biochim Biophys Acta (1996) 0.87
Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. J Clin Invest (1993) 0.87
Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood (1999) 0.87
Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol (1995) 0.86
Adriamycin resistance in human tumor cells associated with marked alteration in the regulation of the hexose monophosphate shunt and its response to oxidant stress. Cancer Res (1987) 0.86
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol (1996) 0.86
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol (1992) 0.86
Identification of 5' and 3' sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem (1993) 0.86
Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein. Cell Death Differ (2000) 0.85
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn J Cancer Res (1996) 0.85
Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. Ann Surg Oncol (1998) 0.85
Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. Biochem Biophys Res Commun (1998) 0.83
Multidrug resistance. Cancer Chemother Biol Response Modif (1993) 0.83
Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res Treat (1999) 0.83
A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res (1997) 0.83
Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines. Int J Cancer (1997) 0.83
Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem (1995) 0.83
Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. Mol Endocrinol (1989) 0.83
Modulation of a human dihydrofolate reductase minigene following release from amino acid deprivation involves both 5' and 3' nucleotide sequences. Mol Pharmacol (1988) 0.83
Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12). Cancer Gene Ther (2000) 0.82
The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys (1992) 0.82
Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells. Anticancer Res (1998) 0.82
Multidrug resistance. Cancer Chemother Biol Response Modif (1990) 0.82
A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis. Cell Death Differ (1999) 0.81
Utilization of multiple polyadenylation signals in the human RHOA protooncogene. Gene (1994) 0.81
Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol (1994) 0.81
Multidrug resistance. Cancer Chemother Biol Response Modif (1999) 0.81
Antineoplastic drug resistance and breast cancer. Ann N Y Acad Sci (1993) 0.81
In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncol Res (1999) 0.81
Adenoviral expression of the cyclin-dependent kinase inhibitor p27Kip1: a strategy for breast cancer gene therapy. J Natl Cancer Inst (1998) 0.81
Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol (1986) 0.81
Multidrug resistance associated with altered topoisomerase II activity--topoisomerases II as targets for rational drug design. J Natl Cancer Inst (1990) 0.80